zacks.com · 10 jul

3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX)

Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.

fxempire.com · 10 jul

Neurocrine Shares Hit Highs on Sales Spike, Strong Pipeline

Biopharmaceutical firm Neurocrine Biosciences, Inc. (NBIX) up over 35% in a year and 17% since outlier inflows in May.

prnewswire.com · 9 jul

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results

Conference Call and Webcast Scheduled for Thursday, July 30 SAN DIEGO, July 9, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m.

247wallst.com · 9 jul

Why Crinetics Stock Soared 99% This Week

Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.

zacks.com · 8 jul

Neurocrine (NBIX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Neurocrine (NBIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

zacks.com · 6 jul

Reasons Why Investors Should Consider Betting on Neurocrine Stock

NBIX builds on Ingrezza's momentum with pipeline advances and the Soleno acquisition, strengthening its long-term neuroscience growth strategy.

seekingalpha.com · 2 jul

Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For Soleno

Neurocrine Biosciences, Inc. remains a Buy, driven by robust growth from Ingrezza, Crenessity, and the recent Vykat acquisition. Q1 2026 revenues rose 44% year-on-year to $811m, with Ingrezza and Crenessity annualizing at blockbuster levels and Vykat showing rapid ramp-up. NBIX stock valuation reflects high-growth expectations; forward P/S ~5.1x and P/E ~30x, justified by an expanding commercial portfolio and pipeline catalysts.

prnewswire.com · 1 jul

Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia

SAN DIEGO, July 1, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 months to under 4 years with classic congenital adrenal hyperplasia (CAH). Crinecerfont, marketed as CRENESSITY®, is approved in the United States as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients 4 years of age and older with classic CAH.